TY - JOUR
AU - Ansell, Benjamin J.
AB - Abstract Context High-density lipoprotein cholesterol (HDL-C) is a cardiovascular risk factor that is gaining substantial interest as a therapeutic target. Objectives To review the current and emerging strategies that modify high-density lipoproteins (HDLs). Data Sources Systematic search of English-language literature (1965-May 2007) in MEDLINE and the Cochrane database, using the key words HDL-C and apolipoprotein A-I and the subheadings reverse cholesterol transport, CVD [cardiovascular disease] prevention and control, drug therapy, and therapy; review of presentations made at major cardiovascular meetings from 2003-2007; and review of ongoing trials from ClinicalTrials.gov and current guidelines from major cardiovascular societies. Study Selection and Data Extraction Study selection was prioritized to identify randomized controlled trials over meta-analyses over mechanistic studies; identified studies also included proof-of-concept studies and key phase 1 through 3 trials of novel agents. Study eligibility was assessed by 2 authors; disagreements were resolved by consensus with the third. Data Synthesis Of 754 studies identified, 31 randomized controlled trials met the inclusion criteria. Currently available therapeutic and lifestyle strategies, when optimized, increase HDL-C levels by 20% to 30%. While basic and small pilot studies have shown promise, proof that increasing HDL-C levels confers a reduction in major cardiovascular outcomes independent of changes in levels of low-density lipoprotein cholesterol or triglycerides has been more elusive. Some novel therapeutic agents in human studies appear to effectively increase HDL-C levels, whereas other novel strategies that target HDL metabolism or function may have minimal effect on HDL-C levels. Conclusions At present there is modest evidence to support aggressively increasing HDL-C levels in addition to what is achieved by lifestyle modification alone. Ongoing clinical trials that target specific pathways in HDL metabolism may help expand cardiovascular treatment options. Despite numerous therapeutic advances, cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in developed countries. Although statins reduce coronary artery disease by approximately 30%,1,2 substantial residual cardiovascular risk remains, even with very aggressive reductions in levels of low-density lipoprotein cholesterol (LDL-C).1,3 Accordingly, attention has shifted toward strategies for targeting high-density lipoprotein (HDL) composition as adjunctive therapy to prevent and treat CVD. In this article, we review published randomized clinical trials that relate to the effect of high-density lipoprotein cholesterol (HDL-C) levels on clinical outcomes and atherosclerosis imaging. Additionally, we discuss epidemiologic observations, proof-of-concept and mechanistic basic science studies, and key phase 1 through 3 trials of novel agents. We also address current guidelines and promising HDL-based strategies and provide clinical suggestions. Data acquisition Assisted by a medical librarian, we performed a systematic search of the English-language literature published from 1965 through May 2007 in MEDLINE and the Cochrane database using the key words HDL-C and apolipoprotein A-I and the subheadings reverse cholesterol transport, CVD prevention and control, drug therapy, and therapy. This search, plus the inclusion of 1 report published subsequent to the May 2007 cutoff,4 yielded 754 studies, of which 357 were randomized controlled trials (Figure 1). We reviewed the abstracts of all of these studies, and in many cases, we analyzed the full-text reports. We extended the search by review of bibliographies from pertinent original reports of data and review articles. Two authors (I.M.S. and M.H.S.) independently assessed each study’s eligibility. When this determination was not unanimous, both authors reviewed the full manuscript and reached consensus with the third author (B.J.A). We prioritized our selection to identify randomized controlled trials over meta-analyses over mechanistic studies. The inclusion criteria were (1) controlled clinical trials of increasing HDL-C levels or otherwise altering the composition of HDL through pharmacological therapy, (2) randomized treatment allocation, and (3) clinical or surrogate (atherosclerotic burden) outcome measures. A total of 31 core studies met our criteria (Figure 1). Our review also includes novel mechanistic or basic science studies providing proof of concept, as well as key preclinical trials of novel agents. Furthermore, we reviewed observational and meta-analysis reports from 1965 to 2007 and abstracts presented at the American Heart Association and American College of Cardiology annual sessions from 2003-2007. We also reviewed position statements and guidelines from the American College of Cardiology, American Heart Association, National Cholesterol Education Program, European Consensus Panel, and American Diabetes Association, as well as ongoing drug trials via ClinicalTrials.gov. Data synthesis Relationship of HDL-C to CVD Quiz Ref IDStudies indicate that low HDL-C levels are relatively common in the general population, with reported rates of HDL-C less than 35 mg/dL (to convert to mmol/L, multiply by 0.0259) of 16% to 18% in men and 3% to 6% in women.5 In addition, low level of HDL-C is a component of the metabolic syndrome, which has a prevalence of 24% in US individuals older than 20 years.6,7 Multiple epidemiologic studies have established a low level of HDL-C as an independent risk factor for CVD.5,8 For example, in the Framingham Heart Study, 43% to 44% of coronary events occurred in persons with HDL-C levels less than 40 mg/dL (22% of the total study population).5 Individuals having HDL-C levels less than 35 mg/dL had an 8-fold higher incidence of CVD compared with those having HDL-C levels of more than 65 mg/dL.5,8 The strength of the relationship between low HDL-C levels and increased CVD risk also is significant in elderly individuals and may be greater in women than in men.5,8,9 Angiographic and ultrasonographic data indicate that low levels of HDL-C are associated with risk and severity of coronary artery disease, carotid disease, and postangioplasty restenosis.9,10 Observational studies have shown that each 1-mg/dL decrease in plasma HDL-C concentration is associated with a 2% to 3% increased risk of CVD.9,10 In addition, each 1-mg/dL increase is associated with a 6% lower risk of coronary death, independent of LDL-C level.9,10 Mechanisms for Protective Effect of HDL Although HDL is thought to protect against CVD, the precise means by which it exerts its antiatherogenic effects are still being characterized. It appears that HDL is likely protective through multiple pathways, including both reverse cholesterol transport and non–cholesterol-dependent mechanisms.11 Reverse Cholesterol Transport. Quiz Ref IDReverse cholesterol transport involves the transfer of excess cholesterol from lipid-laden macrophages (foam cells) present in peripheral tissues to the liver via HDL, with subsequent catabolism of cholesterol or excretion into bile (Figure 2).12 In the vessel wall, cholesterol ester stored in macrophages can be converted to free cholesterol by cholesterol ester hydrolase, whereas acyl-cholesterol acyltransferase can esterify cholesterol within macrophages to form atherogenic foam cells. The liver and intestine synthesize lipid-poor apolipoprotein A-I (apo A-I), which can interact with the adenosine triphosphate–binding cassette transporter A1 (ABCA1) located on the arterial macrophages, transporting free cholesterol to the extracellular lipid-poor HDL. Lipidation of the HDL particles generates nascent (pre-β) HDL.13 Subsequently, lecithin-cholesterol acyltransferase esterifies free cholesterol within nascent HDL to produce mature α-HDL particles (ie, HDL3 [smaller, more dense particles] and HDL2 [larger, less dense particles]). These mature HDL particles can further take up free cholesterol via the macrophage adenosine triphosphate–binding cassette transporter G1. Mature HDL has at least 2 metabolic fates. In the direct pathway, cholesteryl esters contained within HDL can undergo selective uptake by hepatocytes and steroid hormone–producing cells via the scavenger receptor type B1 and subsequent excretion into the bile.12,14 In the indirect pathway, cholesteryl esters within HDL can be exchanged for triglycerides in apolipoprotein B–rich particles (LDL and very low-density lipoprotein [VLDL]) through the action of cholesteryl ester transfer protein (CETP). The subsequent uptake of apolipoprotein B rich in cholesteryl esters by hepatic LDL receptors may be responsible for up to 50% of reverse cholesterol transport.12 The triglyceride-rich HDL can then undergo hydrolysis by hepatic lipase and endothelial lipase to form small HDL for further participation in transport.12 The kidneys appear to play a less understood role in HDL catabolism by controlling the processing rate of lipid-poor apo A-I.14 Non–Cholesterol-Dependent Mechanisms. In addition to its major role in reverse cholesterol transport, HDL has other biological activities that may contribute to its protective effects against atherosclerosis.9,11,15 These include antioxidant (counteracting LDL oxidation) effects, anti-inflammatory effects, antithrombotic/profibrinolytic (reducing platelet aggregation and coagulation) effects, and vasoprotective (facilitating vascular relaxation and inhibiting leukocyte chemotaxis and adhesion) effects.9,11,15,16 Collectively, HDL and its components (including apo A-I, paraoxonase, platelet activating factor acetylhydrolase, and other antioxidant enzymes) exert an array of effects that may help prevent atherosclerosis, acute coronary syndromes, and restenosis after coronary angioplasty.9,17 Functional Heterogeneity of HDL High-density lipoprotein particles can vary substantially in size, density, composition, and functional properties, potentially affecting their relationship to atherosclerosis.11,14,15,18,19 Furthermore, levels of plasma HDL-C do not predict its functionality. Quiz Ref IDAcute or chronic inflammation can adversely influence the normally protective characteristics of HDL. For example, modification of apo A-I within HDL by leukocyte myeloperoxidase renders HDL dysfunctional with proinflammatory and atherogenic properties.20 Patients with CVD or CVD equivalents have elevated levels of proinflammatory HDL compared with healthy controls.21 Furthermore, the inflammatory and anti-inflammatory properties of HDL are better predictors of CVD prevalence than HDL-C alone.21 In the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) population, the large, cholesterol-rich HDL particle, α-1, was the most significant risk factor for recurrent CVD events among HDL particles.22 Rader23 showed that 75% of patients with coronary heart disease (CHD) or CHD equivalents had proinflammatory HDL despite statin therapy. Despite the availability of several techniques to separate HDL by density gradient ultracentrifugation, proton nuclear magnetic resonance, and 2-dimensional gel electrophoresis, studies have not compared the ability of these techniques to predict vascular events. Moreover, mechanistic studies differ as to whether particle size is an important predictor of HDL function; some analyses suggest that small particles are anti-inflammatory, while others indicate that small particles may not be protective in settings of increased oxidative stress.16,19-21 The apolipoproteins within HDL are significant determinants of its function.15 The major HDL apolipoprotein, apo A-I, helps to stimulate the activity of ABCA1 and lecithin-cholesterol acyltransferase and is a ligand for scavenger receptor type B1.14 On the other hand, apo A-II, another component of HDL, has been shown to be proatherogenic in animal models.14 Thus, therapeutic strategies that selectively increase apo A-I levels may be more atheroprotective than those that increase levels of both apo A-I and apo A-II. Nonpharmacological Therapies to Increase HDL-C Levels Aerobic Exercise. Quiz Ref IDFrequent aerobic exercise has been shown to increase HDL-C levels by approximately 5% as early as 2 months from start of regular exercise in sedentary but otherwise healthy individuals through multiple mechanisms (Table 1).24,25 To increase HDL-C levels optimally, individuals should perform five 30-minute sessions of brisk aerobic exercise per week, with total duration of exercise more than 120 minutes per week being the strongest determinant of increased HDL-C levels.42,43 Tobacco Cessation. Tobacco, both smoked and smokeless, reduces levels of HDL-C (Table 1).26 One study showed that HDL-C levels increase by approximately 4 mg/dL following smoking cessation without significant changes in levels of LDL-C, total cholesterol, or triglycerides.27 Tobacco smoke also is a source of oxidative stress that can lead to HDL dysfunction.19 Tobacco cessation should be aggressively promoted via a multidisciplinary approach of counseling and pharmacological agents, as appropriate.42 Weight Loss. Weight loss generally increases HDL-C levels (Table 1) in overweight or obese patients.28 During active weight loss, HDL-C levels decrease slightly; however, when a stable weight reduction is achieved, HDL-C levels increase by 0.35 mg/dL per kilogram of weight lost.29 Weight loss, achieved by lifestyle modifications with or without pharmacological support, has been associated with improved cardiometabolic risk factors.30-32 Overweight and obese individuals should aim to achieve a body mass index (calculated as weight in kilograms divided by height in meters squared) of less than 25 (less than 24 if of Asian descent), at a rate of 2 kg of weight lost per month.42 Alcohol Consumption. Intake of moderate amounts of alcohol (30-40 g [1-3 drinks] per day) increases HDL-C levels and is associated with decreased risk of CHD independent of other factors.33,34 The link between moderate alcohol consumption and decreased cardiovascular risk may reflect the epiphenomenon of a “sick quitter” effect, whereby former alcohol users practice abstinence either due to illness or to medical advice but are misclassified as being nondrinkers.35 Ingestion of 30 to 40 g of alcohol per day for 3 weeks can increase HDL-C levels by as much as 12%, irrespective of the type of alcohol consumed (Table 1).34 However, current guidelines advise no more than 2 drinks per day for men and no more than 1 drink per day for women.42 Persons who do not drink should not be encouraged to initiate regular alcohol consumption. Dietary Factors. Diets rich in saturated fatty acids and trans-fatty acids can increase HDL-C levels but also increase LDL-C levels and HDL-induced expression of proinflammatory endothelial cell adhesion molecules.36 In contrast, diets rich in polyunsaturated fats improve the anti-inflammatory capacity of HDL.36 Substituting dietary saturated fatty acids and trans-fatty acids with monounsaturated fatty acids and polyunsaturated fatty acids reduces the LDL-C:HDL-C ratio.37 Ingestion of n-3 polyunsaturated fatty acids has been associated with increased HDL-C levels and cardiovascular benefits38; however, studies of the cardiovascular effects of n-6 polyunsaturated fatty acids are lacking.39 Replacing saturated fatty acids and trans-fatty acids with low–glycemic index carbohydrates may improve HDL-C profile, but the data are limited.40 Recent data suggest that a low-fat, high-fiber diet for 2 to 3 weeks, in combination with exercise, converts HDL from a proinflammatory to an anti-inflammatory state.25 This improvement in the functional property of HDL occurred despite a mild reduction in levels of HDL-C, suggesting increased turnover of proinflammatory HDL.25 Patients should be advised to replace dietary saturated fatty acids and trans-fatty acids with monounsaturated and polyunsaturated fatty acids sources such as plant oils (olive, canola, soy, mustard, flaxseed), nuts (almonds, peanuts, walnuts, pecans), and marine foods (salmon, tuna, mackerel, marine oils).42 In general, studies using overall lifestyle modifications have shown CVD benefit; however, these beneficial effects cannot solely be attributed to a single strategy or mechanism.30,41 Available Pharmacological Agents That Increase HDL-C Levels Currently available HDL-based therapeutic approaches can be grouped into 2 major categories: agents that increase or modify levels of the HDL components (HDL-C, apo A-I, and phospholipids), and agents that up-regulate reverse cholesterol transport and macrophage cholesterol efflux. Agents That Modify HDL Composition. Nicotinic Acid. First recognized as a treatment for dyslipidemia in 1955, nicotinic acid can increase HDL-C levels by 20% to 30% as well as reduce plasma triglyceride levels by 40% to 50% and LDL-C levels by up to 20% (Table 2).44-56 When tolerated, nicotinic acid represents the most effective HDL-C–increasing agent currently available.9 The most compelling data to support the use of niacin are from the Coronary Drug Project (CDP), which evaluated niacin monotherapy in 8341 men with prior myocardial infarction. In this prestatin study, niacin was associated with a 27% reduction in the incidence of nonfatal reinfarction at 6 years,44 and all-cause mortality was reduced by 11% at 15 years (Table 3).50 Other clinical outcomes studies of niacin have been conducted in the setting of combination therapy, and thus the results should be interpreted in this context. In general, treatment with niacin, both as monotherapy and in combination with other antidyslipidemic agents, has produced consistent clinical and atherosclerotic burden benefit (Table 3). Most of the CVD benefit of niacin can be attributed to its HDL-C–increasing properties (Table 2).9 The therapeutic potential of niacin has been limited by its adverse effects, which can be reduced by use of an extended-release formulation. Use of niacin by patients with diabetes has been cautioned against by the American Diabetes Association, although recent niacin studies have shown no significant increase in long-term glycemic levels, use of oral hyperglycemic regimens, or niacin withdrawal in these patients.85,86 Statins. Statins modestly increase HDL-C levels by 5% to 15%, and this effect is most evident with rosuvastatin.68 The mechanism for statin-induced increase in HDL-C levels is presently unclear, but statins increase levels of apo A-I and lipid-poor HDL and also augment the activity of the antioxidant enzyme paraoxonase (Table 2).69-72 In a recent post hoc analysis of 1455 patients with low HDL-C levels, statins reduced coronary atheroma independent of LDL-C when HDL-C levels were increased by at least 7.5%.73 Statins confer a greater reduction in CVD among patients with lower HDL-C levels, independent of LDL-C effects.74 However, due to their modest effect on HDL-C levels, statins generally are not adequate as monotherapy for increasing HDL-C.75 Agents That Target Reverse Cholesterol Transport and Macrophage Cholesterol Efflux. Fibric acid derivatives (fibrates), which are agonists of peroxisome proliferator–activated receptor (PPAR) α, can increase HDL-C levels (by 10%-20%), modestly lower LDL-C levels (by 10%-15%), and substantially lower levels of triglycerides (by 40%-50%) (Table 2).57,58 Several studies have elucidated the effect of fibrates on reverse cholesterol transport (Table 2).87,88 In the Helsinki Heart Study and the VA-HIT trial, treatment with gemfibrozil was associated with reduction in CVD events (Table 3).57,58 The 22% reduction in coronary events in the VA-HIT trial was attributed to a modest increase (6%) in HDL-C levels.58 In contrast, the results of studies using other fibrates such as bezafibrate and fenofibrate have been negative, while clofibrate has been associated with potential hazard (Table 3).44,57-67,80 Some evidence indicates that the benefits seen in the VA-HIT cohort may be partly due to additional effects of fibrates on apolipoprotein synthesis and lipoprotein metabolism (Table 2).89,90 The combination of fibrates, particularly gemfibrozil, with statins requires caution and monitoring of creatine kinase levels because of the risk for myotoxicity, including rhabdomyolysis.42 Because of this safety concern and variable-outcome study results, the precise role of fibrate treatment remains uncertain but likely includes some patients at high risk of coronary artery disease, low levels of HDL-C, and increased levels of serum triglycerides. The cardiovascular effect of adding fenofibrate to statin therapy is being assessed in a large-scale clinical trial in patients with type 2 diabetes.91 Evolving Novel HDL-Based Therapies Several novel HDL-based therapeutic strategies have been or currently are being tested in phase 1 through 3 clinical trials. These include newer formulations of nicotinic acid/receptor agonists, CETP inhibitors, cannabinoid-1 receptor antagonists, PPAR agonists, liver X receptor/farnesoid X receptor agonists, and apo A-I and/or phospholipid-derived therapies (Table 4). As with current therapies, new HDL-based approaches presently evolving also can be categorized into agents that increase or modify levels of the HDL components and agents that up-regulate reverse cholesterol transport and macrophage cholesterol efflux. Evolving Agents That Modify HDL Composition. Nicotinic Acid–Based Formulations. MK-0524, a selective prostaglandin D2 receptor 1 antagonist, recently demonstrated reduction in nicotinic acid–associated vasodilation and flushing, both in mice and in humans (Table 4).92 The effect of MK-0524 and extended-release niacin on CVD is being assessed in 1 trial of patients with CHD and low HDL-C levels who are receiving statin therapy.110 CETP Inhibitors. Inhibition of CETP activity results in increased HDL-C levels and decreased levels of VLDL, LDL-C, and triglycerides (Table 4).93 Inhibition of CETP also promotes the increase in levels of large, less dense HDL2, an action that may lead to reverse cholesterol transport independent of pre-β- HDL and the ABCA1 pathway.94 Epidemiologic evidence regarding the effects of CETP deficiency has been contradictory.95-97 However, the marked increases in HDL-C levels observed with several developmental compounds with significant CETP inhibitory activity nonetheless prompted the commercial development of these agents. Torcetrapib, a direct CETP inhibitor, has been shown to decrease aortic atherosclerosis in animals and significantly increase HDL-C levels in humans.111-113 However, development of torcetrapib was halted in response to the results of the Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events (ILLUMINATE) trial, which showed a 61% increase in all-cause mortality and other cardiovascular events in individuals at high risk for CHD who were treated with torcetrapib plus atorvastatin compared with those who received placebo plus atorvastatin. Analysis from trials of torcetrapib revealed a mean blood pressure increase of 3 to 4 mm Hg associated with its use, a phenomenon that appears to be molecule-specific and unrelated to CETP inhibition.114 Three other trials with torcetrapib, which evaluated the effect of torcetrapib on coronary atheroma by intracoronary ultrasound and carotid intima-media thickness, showed no change in atherosclerotic burden despite a marked increase in levels of HDL-C (Table 3).4,81,82 While the exact mechanism for increased adverse events in the ILLUMINATE trial is not known, potential explanations include (1) increase in blood pressure and other off-target hemodynamic effects. In ILLUSTRATE there was an average 4.6-mm Hg increase in blood pressure in the torcetrapib group compared with the placebo group. This increase in blood pressure is a torcetrapib-specific toxicity, since such an effect has not been reported with other classes of CETP inhibitors or in animals or patients lacking CETP.98 (2) Production of “dysfunctional” HDL, since CETP inhibition leads to production of α- HDL particles, which are not the preferred ABCA1-mediated cholesterol efflux transporters. (3) Production of “proinflammatory” HDL, possibly through oxidation of phospholipids in “stagnant” HDL particles that result from CETP inhibition.16,20,99 (4) Unforeseen interactions between torcetrapib and atorvastatin. Future studies with other agents in this class that do not affect blood pressure may help clarify the mechanism(s) responsible for failure of torcetrapib.114 The CETP inhibitor JTT-705 reduces CETP activity by 95% in rabbits, accompanied by a 90% increase HDL-C levels, a 40% decrease in non–HDL-C levels, and an 80% decrease in aortic atherosclerosis (Table 4).100 However, data from animal models on the effect of JTT-705 on atherosclerosis have not been consistent. A study in hypercholesteremic rabbits showed that even with similar changes in lipid profiles, JTT-705 did not affect aortic atherosclerosis.101 Potential limitations of these studies were the presence of high levels of total cholesterol and triglycerides, which might counter the beneficial effects of increasing levels of HDL-C. In 2 recent randomized, double-blind, placebo-controlled phase 2 trials, JTT-705 alone or in combination with pravastatin was well tolerated, with no associated increase in blood pressure.98,102 However, to date no clinical outcome trials with JTT-705 have been completed. Apo A-I–Directed Therapies. Current apo A-I–based strategies include infusion of recombinant phospholipids/apo A-I complexes (rHDLs), recombinant proapoliprotein A-I, apo A-I, or apo A-I mimetic peptides, thereby increasing circulating levels of lipid-poor acceptors of cholesterol (Table 4). Weekly rHDL infusions with ETC-216, a recombinant apo A-I Milano (mutant)/phospholipids complex, were shown to promote regression of coronary atheroma plaque after 5 weeks, as measured by intravascular ultrasound, in patients with acute coronary syndromes (Table 3).83 Additionally, the Effect of rHDL on Atherosclerosis–Safety and Efficacy (ERASE) trial evaluated the effect of rHDL in 183 patients with acute coronary syndromes using intravascular ultrasound and angiographic outcomes.84 Compared with placebo, the primary end point of percentage change of atheroma volume with rHDL did not reach significance (Table 3).84 Cholesterol efflux from foam cells via the ABCA1 pathway is one possible antiatherogenic mechanism of these infusion strategies.83,84 Mimetics of the 243–amino acid apo A-I are smaller peptides that resemble the lipid-binding domain of apo A-I and have been shown to possess atheroprotective effects in animal models.105 One such mimetic, L-4F, was shown to improve in vivo vasodilatation and prevent monocyte adhesion, whereas D-4F, an orally active derivative compound that is protected from enzymatic digestion, significantly decreased atherosclerosis in animal models (Table 4).105 The reported mechanism for these actions is the rapid production of β-migrating particles with increased paraoxonase activity, anti-inflammatory capacity, and ability to promote cholesterol efflux from macrophages.105,106,115 Oral administration of D-4F promoted reverse cholesterol transport in both in vitro and in vivo models by accelerating the early steps of reverse cholesterol transport.106 In a phase 1 human trial, a single oral dose of D-4F was associated with improved HDL anti-inflammatory function.23 Results from a parenterally administered peptide, ETC-642, are expected soon. However, these apo A-I–directed therapies do not increase HDL-C levels but rather generate HDL-like particles, modify existing HDL, or both. Phospholipid-Directed Therapies. Phospholipids are an integral component of HDL that also have become a therapeutic target (Table 4).107 In a murine apoE null model, an oral synthetic phospholipid, 1,2-dimyristoyl-sn-glycero-3-phosphocholine, showed an increase in HDL-C and apo A-I levels, along with improvement in HDL function and reduction in aortic lesion size.107 In a small (n = 16) human study, an oral derivative of soy lecithin, phosphatidylinositol, for 2 weeks showed an increase in levels of HDL-C as well as apo A-I (Table 4).108 In addition, infusions of phospholipid particles (eg, phosphatidylcholine or large unilamellar liposomal vesicles) have been proposed to improve reverse cholesterol transport and atherosclerosis regression.109 Cannabinoid-1 Receptor Blockers. Rimonabant, the first selective cannabinoid-1 receptor blocker with anorexant properties, has been shown to increase HDL-C levels by 10%, a phenomenon that is dose-dependent and weight loss–independent (Table 2).31,32 Compared with placebo, patients who received 20 mg of rimonabant had HDL-C levels twice that expected from weight loss alone, suggesting a direct pharmacological effect of rimonabant on lipid metabolism.31,32 Furthermore, HDL-C levels increased continuously throughout the 2-year study, even though body weight stabilized.31,32 Several large-scale trials to assess the effect of rimonabant on clinical outcomes are in progress; however, the drug was denied approval in the United States because of concerns regarding possible central nervous system toxicity. Evolving Agents That Target Reverse Cholesterol Transport and Macrophage Cholesterol Efflux. PPAR agonists currently studied to increase HDL-C levels belong to 3 classes: PPAR-α, PPAR-γ, and PPAR-δ (formerly PPAR-β), all members of the family of nuclear receptor transcription factors involved in fatty acid metabolism.17 Unlike the first-generation PPAR-α agonists (fibrates), newer PPAR-α agonists, eg, NS-220, are more selective and potent (Table 4).103 Another PPAR-α agonist, LY518674, raised safety concerns including increases in levels of creatinine and LDL-C.116 PPAR-γ activators used in type 2 diabetes mellitus, such as thiazolidinediones, increase HDL-C levels by 5% to 15% (Table 2)76,77; however, they have been associated with increased CVD events.78 A PPAR-δ agonist, GW501516, increased HDL-C levels by 80% in a simian model (Table 4).104 The results of a phase 2 human study are pending.117 PPAR agonism has been postulated to increase macrophage cholesterol efflux and the anti-inflammatory properties of HDL.14,17 Dual PPAR- α and PPAR-γ agonists, such as muraglitazar, have been shown to increase HDL-C levels by as much as 16%118,119; however, an analysis of phase 2 and 3 trials of muraglitazar showed a significant increase in the composite end point of all-cause mortality, nonfatal myocardial infarction, stroke, transient ischemic attack, and congestive heart failure, prompting termination of its development.120 Comment Basic science studies and clinical investigations both support the inverse relationship between HDL-C levels and atherosclerosis. HDL augments reverse cholesterol transport and has antioxidative, anti-inflammatory, antithrombotic, and vasoprotective effects.11,15,16 Despite the preponderance of evidence linking low HDL-C levels to cardiovascular morbidity and mortality, there is no definitive evidence proving that increasing HDL-C levels reduces the incidence of major cardiovascular events. Indeed, major clinical guidelines have avoided providing an HDL-C target, despite some consensus statements that increasing HDL-C levels has merit.9,42 Current guidelines from the Adult Treatment Panel III emphasize targeting primarily LDL-C, secondarily non–HDL-C, and then HDL-C.42 The recent American Heart Association/National Heart, Lung, and Blood Institute scientific statement proposes that HDL-C be a “tertiary target” (after LDL-C and triglycerides), with goals of HDL-C levels more than 40 mg/dL in men and more than 50 mg/dL in women.7 The American Diabetes Association proposes that HDL-C be a “secondary target” along with triglycerides, with a goal of HDL-C levels more than 40 mg/dL.121 Both advisories recommend consideration of niacin and fibrates to increase HDL-C levels if lifestyle modifications alone are inadequate.7,121 Evolving HDL-based approaches can be categorized into those that modulate HDL composition (HDL-C, apo A-I, and phospholipids) and those that enhance reverse cholesterol transport. A third category, modulating antioxidant and anti-inflammatory functions of HDL, is common to both of the above approaches and may become an independent strategy of its own. The failure of recently developed agents that substantially increase HDL-C levels suggests that functionality of HDL may be a more appropriate target than HDL-C levels themselves.18,19,99,122 In addition, the relationship between systemic inflammation and HDL function may be particularly relevant.102 The functionality of different HDL subfractions appears to vary substantially. Of the known forms of HDL-C (pre-β-HDL, HDL2, HDL3) pre-β-HDL appears to be the most antiatherogenic form.123 Therefore, therapies that increase the most atheroprotective subfraction(s) of functioning HDL may be most promising. Additionally, functional testing of HDL may provide insight as to the therapeutic promise of investigational compounds. Conclusions While LDL-C–lowering strategies have consistently reduced CHD risk, HDL-based approaches are much more complex and sometimes disappointing. In the last year, the development of pactimibe,124 an acyl-cholesterol acyltransferase inhibitor, and now torcetrapib, have been abandoned. These discontinuations followed prior adverse experiences with some members of the PPAR class.78,116,120 The negative results with these compounds do not refute the concept of increasing HDL-C levels, targeting HDL function, or both to treat atherosclerosis. However, the simple goal of increasing levels of “good” cholesterol can no longer be applied to all forms of HDL without consideration of therapeutic effect on HDL function and ultimately cardiovascular risk. Correlation of HDL functional changes with long-term outcome studies may allow for prospective validation of assays that measure HDL function. Quiz Ref IDIn the meantime, appropriate strategies to increase HDL-C levels include aggressive overall lifestyle modification (exercise, diet, weight loss, and smoking cessation). Patients at increased risk for CHD with low HDL-C levels benefit from niacin and statin therapy, even though the effects of statins on HDL-C levels are relatively modest.73-75 Niacin and fibrate therapy also merit consideration as monotherapies or in closely supervised combination with statin therapy in patients at high risk for CHD. Back to top Article Information Corresponding Author: Mehdi H. Shishehbor, DO, MPH, Cleveland Clinic, 9500 Euclid Ave, JJ40, Cleveland, OH 44195 (shishem@gmail.com). Author Contributions: Dr Singh had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Singh, Shishehbor, Ansell. Acquisition of data: Singh, Shishehbor. Analysis and interpretation of data: Singh, Shishehbor, Ansell. Drafting of the manuscript: Singh, Shishehbor, Ansell. Critical revision of the manuscript for important intellectual content: Singh, Shishehbor, Ansell. Administrative, technical, or material support: Singh, Shishehbor, Ansell. Study supervision: Shishehbor, Ansell. Dr Singh and Dr Shishehbor contributed equally to this manuscript. Financial Disclosures: Dr Ansell reported receiving speaking honoraria from AstraZeneca, Kos Pharmaceuticals, Merck, and Pfizer; receiving research medication from Merck and Pfizer in the past; and having equity interest in Bruin Pharma. No other disclosures were reported. Funding/Support: Dr Shishehbor is supported in part by the National Institutes of Health, National Institute of Child Health and Human Development, Multidisciplinary Clinical Research Career Development Programs grant K12 HD049091 and the National Institutes of Health Loan Repayment Program. Dr Ansell is supported by private philanthropy from Mr and Mrs Timothy Hannemann, Ms Kathleen Kennedy, Mr Frank Marshall, Mr and Mrs Michael Ovitz, and Mr and Mrs Nelson Rising. Role of the Sponsor: Neither the National Institutes of Health nor any of the individuals supporting Dr Ansell through philanthropy had any role in the design and conduct of the study; the collection, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript. Additional Contributions: Alan M. Fogelman, MD (Department of Medicine and Atherosclerosis Research Unit, University of California, Los Angeles), provided thorough and helpful criticisms of the manuscript, and Dave Schumick, BS, CMI (Center for Medical Art and Photography, Cleveland Clinic, Cleveland, Ohio), provided assistance with the figures. Neither received compensation for their contributions. References 1. Cannon CP, Braunwald E, McCabe CH. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495-150415007110Google ScholarCrossref 2. Downs JR, Clearfield M, Weis S. et al. AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279(20):1615-16229613910Google ScholarCrossref 3. LaRosa JC, Grundy SM, Waters DD. et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-143515755765Google ScholarCrossref 4. Bots ML, Visseren FL, Evans GW. et al. RADIANCE 2 Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007;370(9582):153-16017630038Google ScholarCrossref 5. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA. 1986;256(20):2835-28383773200Google ScholarCrossref 6. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356-35911790215Google ScholarCrossref 7. Grundy SM, Cleeman JI, Daniels SR. et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-275216157765Google ScholarCrossref 8. Sharrett AR, Ballantyne CM, Coady SA. et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001;104(10):1108-111311535564Google ScholarCrossref 9. Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid—a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin. 2004;20(8):1253-126815324528Google ScholarCrossref 10. Gordon DJ, Rifkind BM. High-density lipoprotein—the clinical implications of recent studies. N Engl J Med. 1989;321(19):1311-13162677733Google ScholarCrossref 11. Assmann G, Gotto AM Jr. HDL cholesterol and protective factors in atherosclerosis. Circulation. 2004;109(23):(suppl 1) iii8-III1415198960Google Scholar 12. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96(12):1221-123215976321Google ScholarCrossref 13. Curtiss LK, Volenta DT, Hime NJ, Rye KA. What is so special about apolipoprotein AI in reverse cholesterol transport? Arterioscler Thromb Vasc Biol. 2006;26(1):12-1916269660Google ScholarCrossref 14. Meyers CD, Kashyap ML. Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection. Curr Opin Cardiol. 2004;19(4):366-37315218398Google ScholarCrossref 15. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation. 2001;104(19):2376-238311696481Google ScholarCrossref 16. Navab M, Ananthramaiah GM, Reddy ST. et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res. 2004;45(6):993-100715060092Google ScholarCrossref 17. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov. 2005;4(3):193-20515738977Google ScholarCrossref 18. Ansell BJ, Watson KE, Fogelman AM, Navab M, Fonarow GC. High-density lipoprotein function recent advances. J Am Coll Cardiol. 2005;46(10):1792-179816286161Google ScholarCrossref 19. Ansell BJ, Fonarow GC, Fogelman AM. High-density lipoprotein: is it always atheroprotective? Curr Atheroscler Rep. 2006;8(5):405-41116901411Google ScholarCrossref 20. Zheng L, Nukuna B, Brennan ML. et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004;114(4):529-54115314690Google Scholar 21. Ansell BJ, Navab M, Hama S. et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108(22):2751-275614638544Google ScholarCrossref 22. Asztalos BF, Collins D, Cupples LA. et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol. 2005;25(10):2185-219116123324Google ScholarCrossref 23. Rader DJ. Apolipoprotein A-I mimetic peptide D-4F in humans with CHD improves HDL anti-inflammatory function after a single dose [abstract]. Circulation. 2006;114:(suppl) II-288Google Scholar 24. Kraus WE, Houmard JA, Duscha BD. et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med. 2002;347(19):1483-149212421890Google ScholarCrossref 25. Roberts CK, Ng C, Hama S, Eliseo AJ, Barnard RJ. Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors. J Appl Physiol. 2006;101(6):1727-173216902063Google ScholarCrossref 26. Khurana M, Sharma D, Khandelwal PD. Lipid profile in smokers and tobacco chewers—a comparative study. J Assoc Physicians India. 2000;48(9):895-89711198789Google Scholar 27. Maeda K, Noguchi Y, Fukui T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. Prev Med. 2003;37(4):283-29014507483Google ScholarCrossref 28. Weisweiler P. Plasma lipoproteins and lipase and lecithin:cholesterol acyltransferase activities in obese subjects before and after weight reduction. J Clin Endocrinol Metab. 1987;65(5):969-9733667889Google ScholarCrossref 29. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56(2):320-3281386186Google Scholar 30. Burke V, Beilin LJ, Cutt HE, Mansour J, Williams A, Mori TA. A lifestyle program for treated hypertensives improved health-related behaviors and cardiovascular risk factors, a randomized controlled trial. J Clin Epidemiol. 2007;60(2):133-14117208119Google ScholarCrossref 31. Després JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353(20):2121-213416291982Google ScholarCrossref 32. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295(7):761-77516478899Google ScholarCrossref 33. Valmadrid CT, Klein R, Moss SE, Klein BE, Cruickshanks KJ. Alcohol intake and the risk of coronary heart disease mortality in persons with older-onset diabetes mellitus. JAMA. 1999;282(3):239-24610422992Google ScholarCrossref 34. Gaziano JM, Buring JE, Breslow JL. et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med. 1993;329(25):1829-18348247033Google ScholarCrossref 35. Rimm EB, Moats C. Alcohol and coronary heart disease: drinking patterns and mediators of effect. Ann Epidemiol. 2007;17(5):(suppl) S3-S717478322Google ScholarCrossref 36. Nicholls SJ, Lundman P, Harmer JA. et al. Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function. J Am Coll Cardiol. 2006;48(4):715-72016904539Google ScholarCrossref 37. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr. 2003;77(5):1146-115512716665Google Scholar 38. Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med. 1985;312(19):1205-12093990713Google ScholarCrossref 39. Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. 1997;65(5):(suppl) 1645S-1654S9129504Google Scholar 40. Slyper A, Jurva J, Pleuss J, Hoffmann R, Gutterman D. Influence of glycemic load on HDL cholesterol in youth. Am J Clin Nutr. 2005;81(2):376-37915699224Google Scholar 41. Ornish D, Scherwitz LW, Billings JH. et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998;280(23):2001-20079863851Google ScholarCrossref 42. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-249711368702Google ScholarCrossref 43. Kodama S, Tanaka S, Saito K. et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch Intern Med. 2007;167(10):999-100817533202Google ScholarCrossref 44. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231(4):360-3811088963Google ScholarCrossref 45. Blankenhorn DH, Azen SP, Crawford DW. et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation. 1991;83(2):438-4471991366Google ScholarCrossref 46. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257(23):3233-32403295315Google ScholarCrossref 47. Blankenhorn DH, Selzer RH, Crawford DW. et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery: two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation. 1993;88(1):20-288319334Google ScholarCrossref 48. Brown BG, Zhao XQ, Chait A. et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345(22):1583-159211757504Google ScholarCrossref 49. Brown G, Albers JJ, Fisher LD. et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323(19):1289-12982215615Google ScholarCrossref 50. Canner PL, Berge KG, Wenger NK. et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8(6):1245-12553782631Google ScholarCrossref 51. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223(5):405-4183287837Google ScholarCrossref 52. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. JAMA. 1990;264(23):3013-30172243429Google ScholarCrossref 53. Haskell WL, Alderman EL, Fair JM. et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: the Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994;89(3):975-9908124838Google ScholarCrossref 54. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin. 2006;22(11):2243-225017076985Google ScholarCrossref 55. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110(23):3512-351715537681Google ScholarCrossref 56. Whitney EJ, Krasuski RA, Personius BE. et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med. 2005;142(2):95-10415657157Google ScholarCrossref 57. Frick MH, Elo O, Haapa K. et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317(20):1237-12453313041Google ScholarCrossref 58. Rubins HB, Robins SJ, Collins D. et al. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341(6):410-41810438259Google ScholarCrossref 59. Trial of clofibrate in the treatment of ischaemic heart disease: five-year study by a group of physicians of the Newcastle upon Tyne region. Br Med J. 1971;4(5790):767-7754943605Google ScholarCrossref 60. Ischaemic heart disease: a secondary prevention trial using clofibrate: report by a research committee of the Scottish Society of Physicians. Br Med J. 1971;4(5790):775-7844943606Google ScholarCrossref 61. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate: report from the Committee of Principal Investigators. Br Heart J. 1978;40(10):1069-1118361054Google ScholarCrossref 62. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up: report of the Committee of Principal Investigators. Lancet. 1984;2(8403):600-6046147641Google Scholar 63. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000;102(1):21-2710880410Google ScholarCrossref 64. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357(9260):905-91011289345Google ScholarCrossref 65. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 1996;347(9005):849-8538622389Google ScholarCrossref 66. Frick MH, Syvanne M, Nieminen MS. et al. Lopid Coronary Angiography Trial (LOCAT) Study Group. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation. 1997;96(7):2137-21439337181Google ScholarCrossref 67. Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ. 2002;325(7373):113912433762Google ScholarCrossref 68. Jones PH, Davidson MH, Stein EA. et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92(2):152-16012860216Google ScholarCrossref 69. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis. 2002;164(2):361-36912204809Google ScholarCrossref 70. Deakin S, Leviev I, Guernier S, James RW. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol. 2003;23(11):2083-208914500290Google ScholarCrossref 71. Klerkx AH, de Grooth GJ, Zwinderman AH, Jukema JW, Kuivenhoven JA, Kastelein JJ. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur J Clin Invest. 2004;34(1):21-2814984434Google ScholarCrossref 72. Martin G, Duez H, Blanquart C. et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest. 2001;107(11):1423-143211390424Google ScholarCrossref 73. Nicholls SJ, Tuzcu EM, Sipahi I. et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297(5):499-50817284700Google ScholarCrossref 74. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-2212114036Google ScholarCrossref 75. Ansell BJ. Rationale for combination therapy with statin drugs in the treatment of dyslipidemia. Curr Atheroscler Rep. 2005;7(1):29-3315683599Google ScholarCrossref 76. Bavirti S, Ghanaat F, Tayek JA. Peroxisome proliferator-activated receptor-gamma agonist increases both low-density lipoprotein cholesterol particle size and small high-density lipoprotein cholesterol in patients with type 2 diabetes independent of diabetic control. Endocr Pract. 2003;9(6):487-49314715475Google ScholarCrossref 77. Dormandy JA, Charbonnel B, Eckland DJ. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-128916214598Google ScholarCrossref 78. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-247117517853Google ScholarCrossref 79. Kashyap ML, McGovern ME, Berra K. et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol. 2002;89(6):672-67811897208Google ScholarCrossref 80. Keech A, Simes RJ, Barter P. et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849-186116310551Google ScholarCrossref 81. Nissen SE, Tardif JC, Nicholls SJ. et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356(13):1304-131617387129Google ScholarCrossref 82. Kastelein JJ, van Leuven SI, Burgess L. et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356(16):1620-163017387131Google ScholarCrossref 83. Nissen SE, Tsunoda T, Tuzcu EM. et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290(17):2292-230014600188Google ScholarCrossref 84. Tardif JC, Gregoire J, L’Allier PL. et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007;297(15):1675-168217387133Google ScholarCrossref 85. Elam MB, Hunninghake DB, Davis KB. et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. JAMA. 2000;284(10):1263-127010979113Google ScholarCrossref 86. Grundy SM, Vega GL, McGovern ME. et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Arch Intern Med. 2002;162(14):1568-157612123399Google ScholarCrossref 87. Forrester JS, Shah PK. Emerging strategies for increasing high-density lipoprotein. Am J Cardiol. 2006;98(11):1542-154917126667Google ScholarCrossref 88. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98(19):2088-20939808609Google ScholarCrossref 89. Després JP, Lemieux I, Robins SJ. Role of fibric acid derivatives in the management of risk factors for coronary heart disease. Drugs. 2004;64(19):2177-219815456334Google ScholarCrossref 90. Császár A. Hypertriglyceridemia, the coronary heart disease risk marker “solved.” Acta Physiol Hung. 2005;92(2):109-12016268049Google ScholarCrossref 91. Action to Control Cardiovascular Risk in Diabetes (ACCORD) [NCT00000620]. http://www.clinicaltrials.gov/ct/show/NCT00000620?order=1. Accessibility verified July 19, 2007 92. Cheng K, Wu TJ, Wu KK. et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A. 2006;103(17):6682-668716617107Google ScholarCrossref 93. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res. 1993;34(8):1255-12748409761Google Scholar 94. Matsuura F, Wang N, Chen W, Jiang XC, Tall AR. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J Clin Invest. 2006;116(5):1435-144216670775Google ScholarCrossref 95. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23(2):160-16712588754Google ScholarCrossref 96. Curb JD, Abbott RD, Rodriguez BL. et al. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res. 2004;45(5):948-95314967821Google ScholarCrossref 97. Zhong S, Sharp DS, Grove JS. et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest. 1996;97(12):2917-29238675707Google ScholarCrossref 98. Kuivenhoven JA, de Grooth GJ, Kawamura H. et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol. 2005;95(9):1085-108815842977Google ScholarCrossref 99. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM. Mechanisms of disease: proatherogenic HDL—an evolving field. Nat Clin Pract Endocrinol Metab. 2006;2(9):504-51116957764Google ScholarCrossref 100. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000;406(6792):203-20710910363Google ScholarCrossref 101. Huang Z, Inazu A, Nohara A, Higashikata T, Mabuchi H. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci (Lond). 2002;103(6):587-59412444911Google Scholar 102. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF. et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 2002;105(18):2159-216511994249Google ScholarCrossref 103. Kuwabara K, Murakami K, Todo M. et al. A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose levels and modifies lipoprotein profiles in KK-Ay mice. J Pharmacol Exp Ther. 2004;309(3):970-97714982965Google ScholarCrossref 104. Oliver WR Jr, Shenk JL, Snaith MR. et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A. 2001;98(9):5306-531111309497Google ScholarCrossref 105. Navab M, Anantharamaiah GM, Hama S. et al. Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 2002;105(3):290-29211804981Google ScholarCrossref 106. Navab M, Anantharamaiah GM, Reddy ST. et al. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation. 2004;109(25):3215-322015197147Google ScholarCrossref 107. Navab M, Hama S, Hough G, Fogelman AM. Oral synthetic phospholipid (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-null mice. Circulation. 2003;108(14):1735-173914504179Google ScholarCrossref 108. Burgess JW, Neville TA, Rouillard P, Harder Z, Beanlands DS, Sparks DL. Phosphatidylinositol increases HDL-C levels in humans. J Lipid Res. 2005;46(2):350-35515576836Google ScholarCrossref 109. Rodrigueza WV, Klimuk SK, Pritchard PH, Hope MJ. Cholesterol mobilization and regression of atheroma in cholesterol-fed rabbits induced by large unilamellar vesicles. Biochim Biophys Acta. 1998;1368(2):306-3209459607Google ScholarCrossref 110. Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-Thrive [NCT00461630]. http://www.clinicaltrials.gov/ct/show/NCT00461630?order=1. Accessibility verified July 18, 2007 111. Brousseau ME, Schaefer EJ, Wolfe ML. et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350(15):1505-151515071125Google ScholarCrossref 112. Clark RW, Sutfin TA, Ruggeri RB. et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol. 2004;24(3):490-49714739125Google ScholarCrossref 113. Morehouse LA, Sugarman ED, Bourassa PA. et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res. 2007;48(6):1263-127217325387Google ScholarCrossref 114. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol. 2007;27(2):257-26017229967Google ScholarCrossref 115. Navab M, Anantharamaiah GM, Reddy ST. et al. Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol. 2005;25(7):1325-133115831812Google ScholarCrossref 116. Nissen SE, Nicholls SJ, Wolski K. et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA. 2007;297(12):1362-137317384435Google ScholarCrossref 117. GW501516 in Subjects Who Have Low Level of High-Density Lipoprotein Cholesterol [NCT00158899]. http://www.clinicaltrials.gov/ct/show/NCT00158899?order=1. Accessibility verified July 26, 2007 118. Buse JB, Rubin CJ, Frederich R. et al. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther. 2005;27(8):1181-119516199244Google ScholarCrossref 119. Skrumsager BK, Nielsen KK, Muller M, Pabst G, Drake PG, Edsberg B. Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003;43(11):1244-125614551179Google ScholarCrossref 120. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005;294(20):2581-258616239637Google ScholarCrossref 121. Haffner SM. Dyslipidemia management in adults with diabetes. Diabetes Care. 2004;(27):(suppl 1) S68-S7114693930Google Scholar 122. Navab M, Ananthramaiah GM, Reddy ST. et al. The double jeopardy of HDL. Ann Med. 2005;37(3):173-17816019715Google ScholarCrossref 123. Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein. Biochemistry. 1988;27(1):25-293126809Google ScholarCrossref 124. Nissen SE, Tuzcu EM, Brewer HB. et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med. 2006;354(12):1253-126316554527Google ScholarCrossref
TI - High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
JF - JAMA
DO - 10.1001/jama.298.7.786
DA - 2007-08-15
UR - https://www.deepdyve.com/lp/american-medical-association/high-density-lipoprotein-as-a-therapeutic-target-a-systematic-review-PYeRLX8A0t
SP - 786
EP - 798
VL - 298
IS - 7
DP - DeepDyve
ER -